Inhibition of HIV infection through chemoprophyalxis

US9579333B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Walid Heneine · Atlanta, US
• Thomas M. Folks · Helotes, US
• Robert Janssen · Palm Springs, US
• Ronald A. Otten · Villa Rica, US
• Jose Gerardo Garcia Lerma · Decatur, US

Key dates

• Filing date: Apr 6, 2015
• Grant date: Feb 28, 2017
• Expiry date: Apr 6, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/0034
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.